Lyell Immunopharma (LYEL) Revenue & Revenue Breakdown
Lyell Immunopharma Revenue Highlights
Latest Revenue (Y)
$130.00K
Latest Revenue (Q)
$3.00K
Lyell Immunopharma Revenue by Period
Lyell Immunopharma Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $130.00K | -99.85% |
| 2022-12-31 | $84.68M | 695.15% |
| 2021-12-31 | $10.65M | 37.31% |
| 2020-12-31 | $7.76M | 1080.52% |
| 2019-12-31 | $657.00K | - |
Lyell Immunopharma generated $130.00K in revenue during NA 2023, up -99.85% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Lyell Immunopharma Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $3.00K | -76.92% |
| 2023-12-31 | $13.00K | -48.00% |
| 2023-09-30 | $25.00K | -7.41% |
| 2023-06-30 | $27.00K | -58.46% |
| 2023-03-31 | $65.00K | 34.34% |
| 2022-12-31 | $48.39K | 1512.87% |
| 2022-09-30 | $3.00K | -99.99% |
| 2022-06-30 | $35.74M | 6363.11% |
| 2022-03-31 | $553.00K | -80.40% |
| 2021-12-31 | $2.82M | 2.43% |
| 2021-09-30 | $2.75M | 4.83% |
| 2021-06-30 | $2.63M | 7.48% |
| 2021-03-31 | $2.44M | 5.75% |
| 2020-12-31 | $2.31M | 116.07% |
| 2020-09-30 | $1.07M | -65.68% |
| 2020-06-30 | $3.12M | 148.25% |
| 2020-03-31 | $1.26M | - |
Lyell Immunopharma generated $3.00K in revenue during Q1 2024, up -76.92% compared to the previous quarter, and up 6.20% compared to the same period a year ago.
Lyell Immunopharma Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| MRUS | Merus | $43.95M | $11.77M |
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| KRON | Kronos Bio | $6.29M | $2.69M |
| GBIO | Generation Bio | $5.90M | $4.06M |
| CRNX | Crinetics Pharmaceuticals | $4.01M | $640.00K |
| IPSC | Century Therapeutics | $2.23M | $771.00K |
| INBX | Inhibrx Biosciences | $1.80M | - |
| STTK | Shattuck Labs | $1.66M | $1.61M |
| LYEL | Lyell Immunopharma | $130.00K | $3.00K |
| CGEM | Cullinan Oncology | - | - |
| CCCC | C4 Therapeutics | - | - |
| NKTX | Nkarta | - | - |
| MLYS | Mineralys Therapeutics | - | - |
| SANA | Sana Bio | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| EWTX | Edgewise Therapeutics | - | - |
| NUVB | Nuvation Bio | - | $1.44M |
LYEL Revenue FAQ
What is Lyell Immunopharma’s yearly revenue?
Lyell Immunopharma's yearly revenue for 2023 was $130K, representing a decrease of -99.85% compared to 2022. The company's yearly revenue for 2022 was $84.68M, representing an increase of 695.15% compared to 2021. LYEL's yearly revenue for 2021 was $10.65M, representing an increase of 37.31% compared to 2020.
What is Lyell Immunopharma’s quarterly revenue?
Lyell Immunopharma's quarterly revenue for Q1 2024 was $3K, a -76.92% decrease from the previous quarter (Q4 2023), and a -95.38% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $13K, a -48.00% decrease from the previous quarter (Q3 2023), and a -73.13% decrease year-over-year (Q4 2022). LYEL's quarterly revenue for Q3 2023 was $25K, a -7.41% decrease from the previous quarter (Q2 2023), and a 733.33% increase year-over-year (Q3 2022).
What is Lyell Immunopharma’s revenue growth rate?
Lyell Immunopharma's revenue growth rate for the last 3 years (2021-2023) was -98.78%, and for the last 5 years (2019-2023) was -80.21%.